| Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. | |
| | |
MedLine Citation:
|
PMID: 19881243 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We present the case of a 23-year-old man with steroid-resistant nephrotic syndrome due to minimal change disease who was treated with rituximab. The patient was resistant to conventional therapy. We therefore treated him with a single dose of rituximab (375 mg/m(2)). One month after the administration of rituximab, complete remission was achieved. However, six months later, the patient was administered a second dose of rituximab as the peripheral B cell counts began to recover. Thereafter, at present, that is, one year after the first rituximab administration, complete remission has been maintained. We conclude that rituximab may be an effective treatment agent for resistant nephrotic syndrome and the peripheral B cell count may be a useful marker in such patients for preventing disease relapse. |
| | |
Authors:
|
Noritomo Kurosu; Hidekazu Sugiura; Chihiro Iwasaki; Yukari Asamiya; Chiari Kojima; Takahito Moriyama; Mitsuyo Itabashi; Misao Tsukada; Takashi Takei; Tetsuya Ogawa; Takumi Yoshida; Keiko Uchida; Ken Tsuchiya; Kosaku Nitta |
Related Documents
:
|
20831803 - Membranous nephropathy and lupus-like syndrome after hematopoietic cell transplantation... 6649233 - Radiation nephritis causing nephrotic syndrome. 3827283 - The child syndrome. histologic and ultrastructural studies. |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2009-11-02 |
Journal Detail:
|
Title: Internal medicine (Tokyo, Japan) Volume: 48 ISSN: 1349-7235 ISO Abbreviation: Intern. Med. Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-11-02 Completed Date: 2010-01-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9204241 Medline TA: Intern Med Country: Japan |
Other Details:
|
Languages: eng Pagination: 1901-4 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / therapeutic use* Dose-Response Relationship, Drug Drug Resistance / physiology Humans Immunologic Factors / therapeutic use* Male Nephrotic Syndrome / drug therapy*, immunology, physiopathology Remission Induction Steroids / therapeutic use Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunologic Factors; 0/Steroids; 0/rituximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Transient anti-GAD antibody positivity and acute pancreatitis with pancreas tail swelling in a patie...
Next Document: Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS...